Yu-ping Li

Wenzhou Medical University - Department of Pulmonary and Critical Care Medicine

Wenzhou

China

SCHOLARLY PAPERS

1

DOWNLOADS

28

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Apatinib in Patients with Extensive-Stage Small-Cell Lung Cancer After Second or Third-Line Chemotherapy: A Phase II, Single-Arm, Multi-Center, Prospective Study

Number of pages: 44 Posted: 15 May 2019
Chinese Academy of Sciences (CAS) - Department of Medical Thoracic Oncology, Chinese Academy of Sciences (CAS) - Department of Medical Thoracic Oncology, Chinese Academy of Sciences (CAS) - Department of Medical Thoracic Oncology, Chinese Academy of Sciences (CAS) - Department of Medical Thoracic Oncology, Wenzhou Medical University - Department of Pulmonary and Critical Care Medicine, Wenzhou Medical University - Department of Pulmonary and Critical Care Medicine, Yinzhou People’s Hospital - Department of Radiotherapy and Chemotherapy, Chinese Academy of Sciences (CAS) - Department of Radiation Oncology, Chinese Academy of Sciences (CAS) - Department of Medical Thoracic Oncology, Chinese Academy of Sciences (CAS) - Department of Medical Thoracic Oncology, Chinese Academy of Sciences (CAS) - Department of Medical Thoracic Oncology, Chinese Academy of Sciences (CAS) - Department of Medical Thoracic Oncology, Chinese Academy of Sciences (CAS) - Department of Medical Thoracic Oncology, Chinese Academy of Sciences (CAS) - Department of Medical Thoracic Oncology, Chinese Academy of Sciences (CAS) - Department of Medical Thoracic Oncology, Chinese Academy of Sciences (CAS) - Department of Medical Thoracic Oncology, Chinese Academy of Sciences (CAS) - Department of Medical Thoracic Oncology, Chinese Academy of Sciences (CAS) - Department of Medical Thoracic Oncology, Chinese Academy of Sciences (CAS) - Good Clinical Practice Center and Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer
Downloads 28 (1,061,485)

Abstract:

Loading...

apatinib, extensive-stage small-cell lung cancer, phase II